A new ICT-based device (RHEO-01) for fast point-of-care analysis of acute ischemic stroke and other emergency situations.

Project Information

ERYTHROAG

Grant agreement ID: 735480

DOI

10.3030/735480

Project closed

EC signature date 24 July 2016

Start date 1 August 2016

End date 31 January 2017

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

RHEOFAST
France

Periodic Reporting for period 1 - ERYTHROAG (A new ICT-based device (RHEO-01) for fast point-of-care analysis of acute ischemic stroke and other emergency situations.)

Reporting period: 2016-08-01 to 2017-01-31

Summary of the context and overall objectives of the project

Stroke is the most frequent cause of long-term disability in Europe, mainly in middle-aged and elderly people. Stroke imposes a huge health care economic burden: >5B€/year in France.
RHEOFAST's RHEO-01 is a disruptive ICT-based smart decision support tool for medical emergency management. This tool will provide the physician with personalized patient’s health status assessment in a few minutes. It has three components which have to be evaluated:
- Fast, easily and highly reliable measurement of erythrocyte aggregation kinetics (EAK), a new biomarker of inflammation, and its medical relevance.
- Remote smart data processing and comparison with a reference dataset.
- Physician-friendly results for fast decision support.
This tool can be used in emergency vehicles and at the point of care.
In this phase 1, we evaluated whether RHEO-01 concept is feasible from a technical and a financial point of view and whether acute stroke management is the best indication for RHEO-01

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

With the most extensive clinical programme ever conducted and evaluating erythrocyte aggregation in clinical setting (1,300 measurements in 500 subjects) we were able to build and test a high-accuracy measurement of EAK, as well as to define the technical requirements for the smart data processing of EAK information. Our technique is well protected (pending PCT patents). Contrary to our initial hypothesis, both our clinical trials and our market analysis showed that the most promising indication for our product may likely be the management of acute chest pain suspected of heart attack. As for stroke management, timesaving is critical for improving the management and treatment of victims of heart attacks.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Cardiovascular disease remains the leading cause of death in Europe (42%), including coronary heart disease (20%) and stroke (10%). CVD is also the leading cause of years lived with disabilities in Europe.
By providing key, fast information for the appropriate orientation of patients suspected of heart attack, RHEO-01 might be able to improve patients survival, limit myocardial infarct size and, thereby chronic heart failure in these patients.

RHEOFAST